Valuation: IN8bio, Inc.

Market Cap 13.1M 11.45M 10.56M 9.73M 18.35M 1.26B 18.76M 126M 49.65M 618M 49.18M 48.11M 2.13B P/E 2026 *
-1.07x
P/E 2027 * -1.25x
Enterprise Value 13.1M 11.45M 10.56M 9.73M 18.35M 1.26B 18.76M 126M 49.65M 618M 49.18M 48.11M 2.13B EV / Sales 2026 *
-
EV / Sales 2027 * 15.8x
Free-Float
86.6%
Yield 2026 *
-
Yield 2027 * -
1 day-3.62%
Current month-5.67%
1 month-6.99%
3 months-7.64%
6 months-48.65%
Current year-43.16%
1 week 1.31
Extreme 1.31
1.46
1 month 1.28
Extreme 1.28
1.53
Current year 1.28
Extreme 1.28
2.73
1 year 1.17
Extreme 1.17
2.73
3 years 1.17
Extreme 1.17
74.4
5 years 1.17
Extreme 1.17
309.57
10 years 1.17
Extreme 1.17
309.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 2018-10-31
Chief Executive Officer 50 2015-10-31
Director of Finance/CFO 43 2021-02-07
Director TitleAgeSince
Director/Board Member 50 2015-10-31
Director/Board Member 68 2019-06-30
Director/Board Member 64 2021-08-03
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Don

Director

-724,637 7.3589%
5/9/26 Free

Director

22,000 0.2234%
5/9/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
-3.62%0.00%-38.71%-97.14% 13.1M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.86%-2.36%+32.62%+155.93% 23.36B
Weighted average by Cap. -2.80%-2.36%+39.54%+143.11%

Financials

2026 *2027 *
Net sales - 830K 725K 669K 617K 1.16M 79.91M 1.19M 8M 3.15M 39.13M 3.12M 3.05M 135M
Net income -22.29M -19.48M -17.98M -16.57M -31.23M -2.15B -31.93M -215M -84.52M -1.05B -83.72M -81.89M -3.62B -25.76M -22.52M -20.78M -19.15M -36.1M -2.48B -36.9M -248M -97.67M -1.22B -96.76M -94.63M -4.18B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
18
Date Price Change Volume
26-07-17 US$1.330 -3.62% 65,504
26-07-16 US$1.380 -4.17% 105,006
26-07-15 US$1.440 +4.35% 75,314
26-07-14 US$1.380 +2.99% 16,249
26-07-13 US$1.340 +0.75% 76,141
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.330USD
Average target price
6.250USD
Spread / Average Target
+369.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock